Confusion Over CLIA QC For POCTs Persists; CMS Guidance Forthcoming
This article was originally published in The Gray Sheet
Executive Summary
CMS will provide guidance for laboratories and the agency's regional offices to clarify implementation procedures detailed in the CLIA Quality Control (QC) final rule in the next several weeks
You may also be interested in...
CLIA Surveyor Guidelines To Expand Labs’ Alternative Quality Control Options
Laboratories performing non-waived diagnostic tests subject to CLIA quality control rules are granted a two-year reprieve from QC enforcement actions by the Centers for Medicare & Medicaid Services
FDA Review Of CLIA Lab Test QC Instructions Not Needed – CMS Quality Rule
Manufacturer-provided quality control instructions for clinical lab assays will not be subject to FDA review, the Centers for Medicare & Medicaid Services declares in its Jan. 24 final rule on CLIA quality systems
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.